Treatment of the Superior Sulcus Tumor by Irradiation Followed by Resection

Shaw, Robert R.; Paulson, Donald L.; Kee, John L.

doi:10.1097/00000658-196107000-00003

Cited by 324 publications

(137 citation statements)

References 3 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…Less than 5% of all bronchogenic carcinomas evolve into Pancoast tumors (9). Initially Pancoast tumors seemed to have different biology from that of other non-small cell lung cancers (NSCLC), with higher propensity for local invasion and diminished incidence of spread through lymphatic or haematogenous lines (10). However, as pointed out by Detterbeck (11), the rates of pathologic N2 involvement in resected patients are not any different from those of other clinically stage matched NSCLC, and survival rates are better when lobectomy is performed rather than wedge resection.…”

Section: Etiology and Biologymentioning

confidence: 99%

See 1 more Smart Citation

Superior sulcus tumors (Pancoast tumors)

et al. 2016

View full text Add to dashboard Cite

Section: Etiology and Biologymentioning

confidence: 99%

“…This was the first surgical approach described by Shaw and Paulson (10). The incision extends around the tip of the scapula and reaches midway between the posterior edge of the scapula and the spinous processes, up to the level of C7.…”

Section: High Postero-lateral Approach (Figure 5)mentioning

confidence: 99%

Superior sulcus tumors (Pancoast tumors)

et al. 2016

View full text Add to dashboard Cite

“…U ntil the early 1990s, standard therapy of Pancoast tumour (superior sulcus tumour (SST)) was based on local treatment modalities (surgery, radiotherapy or a combination of both) under the assumption that SST is a locally invasive disease and that the prognosis could be improved mainly by achieving an effective local control [1][2][3][4][5]. Thereafter, Pancoast tumour with ipsi-or contralateral mediastinal lymph node metastases has been, and continues to be, considered as a prognostically inoperable disease.…”

mentioning

confidence: 99%

Induction chemotherapy, concurrent chemoradiation and surgery for Pancoast tumour

Marra¹,

Eberhardt²,

Pöttgen³

et al. 2006

European Respiratory Journal

View full text Add to dashboard Cite

The traditional treatment of Pancoast tumour with local approaches (surgery, radiotherapy or a combination of both) leads to a poor outcome due to the high rate of incomplete resection and the lack of systemic control. The aim of the present prospective feasibility study was to determine whether a trimodality approach improves local control and survival.Patients with stage IIB-IIIB Pancoast tumour received induction chemotherapy (three courses of split-dose cisplatin and etoposide or paclitaxel) followed by concurrent chemoradiotherapy (a course of cisplatin/etoposide combined with 45 Gy hyperfractionated accelerated radiotherapy). After restaging, eligible patients underwent surgery 4-6 weeks post-radiation.A total of 31 consecutive patients with T3 (81%) or T4 (19%) Pancoast tumour were enrolled in the study. Induction chemoradiotherapy was completed in all patients without treatment-related deaths. Grade 3-4 toxicity was observed in 32% of cases. In total, 29 (94%) patients were eligible for surgery. Complete resection was achieved in 94% of patients. The post-operative mortality rate was 6.4% and major complications arose in 20.6% of the patients. The median survival was 54 months with 2-and 5-yr survival rates of 74 and 46%, respectively.In conclusion, this intensive multimodality treatment of Pancoast tumour is feasible and improves local resectability rates and long-term survival as compared with historical series.

show abstract

“…Allerede på 60-tallet ble det klart at preoperativ strålebehandling ga bedre resultater enn kirurgi alene (229). Induksjonsbehandling med kjemoterapi alene gir lave responsrater (213).…”

Section: Konkomitant Kjemoradioterapiunclassified